M&G Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

M&G Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-246,098	Closed	-$6.15M	–	399
2023 Q2	$6.15M	Buy	+246,098	New	+$7.67M	0.02%	260
2021 Q4	–	Sell	-56,621	Closed	-$1.58K	–	765
2021 Q3	$1.58K	Buy	+56,621	New	+$1.62M	﹤0.01%	546

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

M&G Investment Management's RVNC Position: Q3 2023 in Review

M&G Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 246,098 shares — an estimated $6.15M sold.

M&G Investment Management first reported a position in RVNC in Q3 2021 and held it in 2 quarters. The position peaked at $6.15M in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

M&G Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
M&G Investment Management sold 246,098 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $6.15M.
M&G Investment Management first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 2 quarters.
M&G Investment Management's Revance Therapeutics, Inc. position peaked at $6.15M in Q2 2023.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on M&G Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.